Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
629.8
1 302
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
Accounts Receivables
Zydus Lifesciences Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Accounts Receivables
₹52.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Accounts Receivables
₹80.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Accounts Receivables
₹55.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Accounts Receivables
₹129.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
14%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Accounts Receivables
₹17.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Accounts Receivables
₹8.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zydus Lifesciences Ltd
Glance View
Zydus Lifesciences Ltd. is a prominent player in the pharmaceutical landscape, rooted in its rich history and unwavering commitment to innovation. Founded in 1952, the company has evolved from a small enterprise into a global entity, driven by its ambition to provide high-quality and affordable healthcare solutions. With a diverse portfolio that encompasses both generic and branded pharmaceuticals, biosimilars, and consumer health products, Zydus has positioned itself as a key contributor to addressing pressing health needs worldwide. Its state-of-the-art manufacturing facilities and robust R&D capabilities reflect a deep investment in creating cutting-edge therapies that appeal to a growing patient base globally. For investors, Zydus Lifesciences presents a compelling opportunity fueled by strategic expansion and strong financial performance. The company's recent foray into the biopharmaceutical sector, backed by successful launches of innovative therapies and the development of complex generics, indicates a clear path for sustainable growth. Moreover, Zydus has demonstrated resilience in navigating regulatory challenges and market fluctuations, enabling it to establish a solid presence in established and emerging markets alike. As healthcare dynamics shift towards personalized medicine and advanced biologics, Zydus is poised not only to adapt but to lead in these areas, making it an enticing consideration for investors looking to be part of a forward-thinking healthcare company with a solid foundation.
See Also
What is Zydus Lifesciences Ltd's Accounts Receivables?
Accounts Receivables
52.3B
INR
Based on the financial report for Jun 30, 2024, Zydus Lifesciences Ltd's Accounts Receivables amounts to 52.3B INR.
What is Zydus Lifesciences Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
17%
Over the last year, the Accounts Receivables growth was 18%. The average annual Accounts Receivables growth rates for Zydus Lifesciences Ltd have been 19% over the past three years , 6% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
